Fat jabs and Wegovy: what's behind the nickname

You've heard the nickname — here's what's actually in the pen

Picture yourself scrolling through headlines: 'celebrity fat jab', 'weight-loss jab shortage', 'NHS fat jab rollout'. The phrase gets used interchangeably for at least three different medicines, which causes a lot of confusion. Wegovy is semaglutide, made by Novo Nordisk, and it is the GLP-1 injection that holds a UK licence specifically for weight management. GLP-1 stands for glucagon-like peptide-1, a hormone your gut releases naturally after a meal. Semaglutide mimics that hormone, signalling to the brain that you've eaten, slowing gastric emptying, and reducing the drive to keep eating.

The result is that people tend to feel satisfied on smaller portions and find it easier to stick to reduced food intake over time. That's the biological mechanism — not willpower, not a shortcut. If you want a fuller picture of how semaglutide works and what the injection schedule looks like, the semaglutide overview on our treatment pages covers the licensed pathway in plain language. The NHS also publishes patient-level detail on the NHS semaglutide medicine page, which is worth bookmarking.

One quick habit worth building: before you read anything about buying these medicines online, take thirty seconds to check whether the pharmacy is listed on the GPhC register at pharmacyregulation.org. If it isn't there, stop.

What Wegovy is licensed for, and who the nickname leaves out

The phrase 'fat jab' is used loosely enough that it sometimes refers to tirzepatide (Mounjaro), Saxenda, or even Ozempic, which is semaglutide but licensed for type 2 diabetes, not weight loss. Wegovy's licence in the UK covers adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related health condition such as high blood pressure, high cholesterol, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance.

Eligibility isn't just a number on a chart, though. A prescriber looks at your full health picture: other medicines you take, any history of pancreatitis, thyroid conditions, and whether you're pregnant or planning to become pregnant, among other things. Wegovy is not recommended during pregnancy, breastfeeding, or for anyone under 18. The MHRA granted it Black Triangle status, which means prescribers and patients report any suspected side effects so the safety profile continues to be monitored closely. If you're weighing up whether this type of treatment could suit you, the weight-loss jabs Wegovy page covers the eligibility picture in more detail.

Thinking about cost at this stage is natural. For context on what private treatment typically involves, our Wegovy treatment page sets out what's included in one transparent price.

What the clinical trial evidence actually showed

The STEP 1 trial ran for 68 weeks and enrolled adults living with obesity who did not have type 2 diabetes. Those taking semaglutide 2.4 mg lost around 15% of their body weight on average, compared with around 2.4% in the placebo group, alongside a reduced-calorie diet and increased physical activity. That's a meaningful difference, published in the New England Journal of Medicine (STEP 1, 2021). Weight loss varied between individuals; these are averages from a controlled trial, not a guarantee of what you would experience.

NICE reviewed that evidence and recommended semaglutide for NHS use under specific conditions, including use within a specialist weight management service for a maximum of two years. The semaglutide fat jab page goes further on how NHS and private access differ in practice. Briefly: NHS access remains subject to strict eligibility criteria and, in many areas, significant waiting times. A regulated private pharmacy is the alternative route for people who don't meet current NHS thresholds or prefer not to wait, provided they meet the licensed clinical criteria.

Side effects, safety, and what to watch for

The most common side effects are gastrointestinal: nausea, vomiting, loose stools, constipation, and bloating tend to be most noticeable during the first weeks of treatment or after a dose increase, and they often ease as the body adjusts. Fatigue and mild headache are also reported. These are well-documented effects rather than surprises, and most people manage them by eating smaller meals, staying hydrated, and eating slowly.

More serious but less common effects include acute pancreatitis. The MHRA issued a Drug Safety Update in January 2026 reminding prescribers and patients to seek urgent medical attention for severe, persistent stomach pain that radiates to the back. If you experience that symptom, don't wait to see whether it passes. Report any suspected side effects, including reactions to medicines you suspect may not be genuine, via the MHRA Yellow Card scheme. The semaglutide jabs page covers the side-effect picture in more depth, including what the injection process itself involves day to day, and our Wegovy jabs page is a good companion read if you want to understand the pen device and dose titration steps before you commit. And if you'd like to understand the clinical team behind the prescribing decisions at our pharmacy, our clinical lead's profile is worth a read.

If after reading all of this you think Wegovy might be worth exploring, the right next step is a clinical conversation. Check your eligibility with our prescribers, the consultation is free, reviewed the same day by a GPhC-registered Independent Prescriber, and there is no obligation to proceed.